InnoCare Pharma Limited
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- InnoCare Pharma Limited (HKEX: 09969; SSE: 688428; OTC: INCPF), a commercial-stage biopharmaceutical company founded in 2015 and headquartered in Beijing, China, discovers, develops, manufactures, and commercializes innovative drugs targeting cancer and autoimmune diseases with significant unmet needs; its operations span China, Hong Kong, the United States, Singapore, and Australia through sites in Beijing, Nanjing, Shanghai, Guangzhou, and beyond. Core products include the marketed BTK inhibitor orelabrutinib (brand name HIBRUKA), approved in China for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (r/r CLL/SLL), mantle cell lymphoma (r/r MCL), and marginal zone lymphoma (r/r MZL), all included in China's National Reimbursement Drug List, as well as approved in Singapore for r/r MZL; tafasitamab, a CD19-targeted immunotherapy licensed for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) in Hong Kong, Macau, Taiwan, Bo'ao, and the Greater Bay Area, with its biologics license application accepted for priority review by China's NMPA; and an extensive clinical pipeline featuring ICP-248 (mesutoclax), a BCL-2 selective inhibitor in Phase III for first-line CLL/SLL and r/r MCL in combination with orelabrutinib, ICP-490, a molecular glue degrader for multiple myeloma and non-Hodgkin lymphoma, ICP-B02 (CM355), a CD20xCD3 bispecific antibody for B-cell malignancies, ICP-332 (soficitinib), a TYK2 JH1 inhibitor in Phase III for atopic dermatitis, ICP-488, a TYK2 JH2 allosteric inhibitor in Phase III for plaque psoriasis, zurletrectinib (ICP-723), a pan-TRK inhibitor completing Phase II for NTRK fusion-positive solid tumors with NDA submission planned by end-March 2025, gunagratinib (ICP-192), a pan-FGFR inhibitor for cholangiocarcinoma, ICP-189, an SHP2 allosteric inhibitor in combination trials for non-small cell lung cancer, and preclinical assets including novel ADCs like ICP-B794 targeting B7-H3 and CCR8 antibody ICP-B05. Recent developments encompass a October 2025 licensing agreement with Zenas BioPharma granting ex-China rights to orelabrutinib for autoimmune indications like multiple sclerosis, plus two preclinical assets, valued at over $2 billion in potential milestones including $100 million upfront/near-term payments and 7 million Zenas shares; a January 2025 deal with Prolium Bioscience for ICP-B02 rights outside oncology globally and oncology ex-Asia, potentially worth $520 million plus royalties and equity; FDA agreements in 2024-2025 for Phase III orelabrutinib trials in primary/secondary progressive multiple sclerosis and approvals for mesutoclax in AML/MDS; first-patient dosings in 2025 for novel ADC ICP-B794, Phase III mesutoclax for BTKi-treated MCL, and ICP-488 Phase III; NDA acceptances for orelabrutinib first-line CLL/SLL in China and r/r MCL in Australia; 49.1% orelabrutinib revenue growth to RMB 1.0 billion in 2024 driving total revenue up 36.7% to RMB 1.01 billion; and advancements like zurletrectinib priority review and ICP-332 U.S. Phase I completion.
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
Phase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULAR
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
InnoCare Announces Approval of Orelabrutinib in Australia
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
InnoCare Pharma Limited (INCPF) Q4 2025 Earnings Call Transcript
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China
InnoCare Announces Key Developments of Critical Clinical Studies
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
Over 20 Studies of InnoCare's Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis